Jai-Hyun Kim
Associate Project Scientist, Department of Neurology, School of Medicine, UC Irvine
Biography
Jai-Hyun Kim, Ph.D., is an Associate Project Scientist in the Department of Neurology at the University of California, Irvine School of Medicine. Kim received a Ph.D. in Biochemistry and Biomaterial Science from Yonsei University in Seoul, Korea, where his dissertation focused on the characterization of promoters of cholesterogenic enzymes. His research spans cancer biology, angiogenesis, and molecular biology, with experience across industrial research, academic institutions, and hospital research settings.
Kim's research career includes postdoctoral training at the University of Texas MD Anderson Cancer Center, where he investigated transcription clustering in bladder cancer using cDNA microarray technology and studied the anticancer activity of IGFBP-3 and Akt inhibitors in breast cancer. He subsequently worked as a Research Associate at Baylor College of Medicine, developing protein networks using DNA microarray technology. From 2009 to 2013, Kim served as an Associate Specialist at UC Irvine's Molecular Biology and Biochemistry Department and Stem Cell Research Center, where he managed laboratory operations and led projects on angiogenesis mechanisms, including the BMP9-Alk1-EphrinB2 pathway in arteriovenous malformation and three-dimensional culture systems for endothelial cells.
Kim has authored over two dozen peer-reviewed publications in journals including Blood, Cell, Journal of Biological Chemistry, and Clinical Cancer Research. His work has addressed topics ranging from cholesterol biosynthesis and antifungal mechanisms to tumor angiogenesis and cancer therapeutics. Prior to his academic career, Kim worked as a Research Scientist at ChoongWae Pharma Corporation in South Korea, where he contributed to the development of anti-HBV agents and anticancer drugs. He holds multiple patents related to antiviral compounds and has received recognition including an Award for a Man of Science Merit from Korea's Ministry of Science, ICT and Future Planning.
Return to topEducation
- Ph.D. in Biochemistry & Biomaterial Science, Yonsei University, 2001
- M.Sc. in Biochemistry, Hanyang University, 1992
- B.S. in Biochemistry, Hanyang University, 1990
Distinctions
- Travel Fellowship Award and Best Poster Prize, 14th FAOBMB New Zealand Symposium, 1999
- Award for a man of Science Merit, Ministry of Science, ICT & Future Planning, Korea, 2013
- Best Poster Presentation Award, UT MD Anderson Cancer Center, 2004
Areas of Expertise
- Cancer Biology and Therapeutics
- Bispecific Antibody Engineering
- Angiogenesis Inhibition Mechanisms
- Tumor Microenvironment Immunotherapy
- Cholesterol Biosynthesis Regulation
- Antifungal Drug Development
- Graphene Biosensor Technology
Recent Publications
- Zhou RW, Purohit PK, Kim JH, Lee SU, Burshteyn N, Tifrea D, Cordon A, Grigorian A, Newton BL, Edwards RA, Demetriou M, “Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens” (opens in new tab), Cell, vol. 188, pp. S0092-8674(25)01032-3, 2025.
- Liau MC, Kim JH, Fruehauf JP, “Arachidonic acid and its metabolites as surveillance differentiation inducers to protect healthy people from becoming cancer patients”, Clin Pharmacol Toxicol Res, vol. 4, no. 1, pp. 1-5, 2021.
- MC Liau, JH Kim, JP Fruehauf, “An Approach in Pursuance of Differentiation Inducers to Combat Cancer via Targeting of Abnormal Methylation Enzymes”, Highlights on Medicine and Medical Research Vol. 2, Book Publisher International, pp. 69-78, 2021.
- Ming C. Liau, Jai-Hyun Kim, John P. Fruehauf, “Study on Potentiation of ATRA Activity in HL-60 Cells by Targeting Methylation Enzymes”, New Frontier in Medicine and Medical Research, vol. 11, pp. 10-22, 2021.
- Ming C. Liau, Jai-Hyun Kim, John P. Fruehauf, “Arachidonic acid and its metabolites as differentiation inducers for the perfection of wound healing to avoid cancer and to beat cancer” (opens in new tab), Current Aspect in Pharmaceutical Research and Development Vol.1, pp. 158-167, 2021.
- MC Liau, JH Kim, JP Fruehauf, “In Pursuance of Differentiation Inducers to Combat Cancer via Targeting of Abnormal Methylation Enzymes”, Journal of Cancer and Tumor International, vol. 10, no. 2, pp. 39-47, 2020.
- MC Liau, JH Kim, JP Fruehauf, “Destabilization of Abnormal Methylation Enzymes to Combat Cancer. The Nature's Choice to Win the War on Cancer”, LAP Lambert Academic Publishing, 2020.
- Parmakhtiar B, Burger RA, Kim JH, Fruehauf JP, “HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity” (opens in new tab), Mol Cancer Res, vol. 17, no. 8, pp. 1675-1686, 2019.
- Liau MC, Kim J-H, Fruehauf JP, “Potentiation of ATRA Activity in HL-60 Cells by Targeting Methylation Enzymes”, J Pharmacol Pharmaceut Pharmacovig, vol. 3, pp. 009, 2019.
- Liau MC, Kim J-H, Fruehauf JP, “Destabilization of Abnormal Methylation Enzymes: Nature's way to Eradicate Cancer Stem Cells” (opens in new tab), J Complement & Alt Med, vol. 2, no. 5, pp. 1, 2019.
- Fruehauf JP, Farrokh N, Sarkissian S, Kim J-H, “Blockade of ARV7:HIF1α; heterodimers after toptoecan reverses enzalutamide resistance in 22Rv1 cells”, Cancer Research, vol. 77, no. 6, pp. A37, 2017.
- John P. Fruehauf, Nathan Farrokhian, Sarmen Sarkissian, Jai-Hyun Kim, “Blockade of ARV7:HIF1α heterodimers after topotecan reverses enzalutamide resistance in 22Rv1 cells”, Journal of Clinical Oncology, vol. 34, no. 15_suppl, pp. e16594, 2016.
- Szabo S, Deng X, Xiong X, Sandor Zs, Kim J-H, “New and Old Concepts of Cell Death and Tissue Injury: Necrosis, Apoptosis and Necroptosis”, Digestive Diseases and Sciences, vol. 59, pp. 1663-1664, 2014.
- Suh YA, Kim JH, Sung MA, Boo HJ, Yun HJ, Lee SH, Lee HJ, Min HY, Suh YG, Kim KW, Lee HY, “A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer” (opens in new tab), Cancer Lett, vol. 332, no. 1, pp. 102-9, 2013.
- Benzinou M, Clermont FF, Letteboer TG, Kim JH, Espejel S, Harradine KA, Arbelaez J, Luu MT, Roy R, Quigley D, Higgins MN, Zaid M, Aouizerat BE, van Amstel JK, Giraud S, Dupuis-Girod S, Lesca G, Plauchu H, Hughes CC, Westermann CJ, et al., “Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia” (opens in new tab), Nat Commun, vol. 3, pp. 616, 2012.
- Oh SH, Kim WY, Lee OH, Kang JH, Woo JK, Kim JH, Glisson B, Lee HY, “Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma” (opens in new tab), Cancer Sci, vol. 103, no. 7, pp. 1259-66, 2012.
- Kim JH, Peacock MR, George SC, Hughes CC, “BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II” (opens in new tab), Angiogenesis, vol. 15, no. 3, pp. 497-509, 2012.
- Kim JH, Choi DS, Lee OH, Oh SH, Lippman SM, Lee HY, “Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events” (opens in new tab), Blood, vol. 118, no. 9, pp. 2622-31, 2011.
- Baruscotti I, Barchiesi F, Jackson EK, Imthurn B, Stiller R, Kim JH, Schaufelberger S, Rosselli M, Hughes CC, Dubey RK, “Estradiol stimulates capillary formation by human endothelial progenitor cells: role of estrogen receptor-{alpha}/{beta}, heme oxygenase 1, and tyrosine kinase” (opens in new tab), Hypertension, vol. 56, no. 3, pp. 397-404, 2010.
- Kim JH, Zhao Y, Pan X, He X, Gilbert HF, “The unfolded protein response is necessary but not sufficient to compensate for defects in disulfide isomerization” (opens in new tab), J Biol Chem, vol. 284, no. 16, pp. 10400-8, 2009.
- Crampton SP, Wu B, Park EJ, Kim JH, Solomon C, Waterman ML, Hughes CC, “Integration of the beta-catenin-dependent Wnt pathway with integrin signaling through the adaptor molecule Grb2” (opens in new tab), PLoS One, vol. 4, no. 11, pp. e7841, 2009.
- Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY, “Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma”, Clin Cancer Res, vol. 12, no. 2, pp. 653-61, 2006.
- Kim JH, Hwang EH, Park HJ, Paik YK, Shim YH, “Methylation of CpG islands in the rat 7-dehydrocholesterol reductase promoter suppresses transcriptional activation”, Mol Cells, vol. 19, no. 2, pp. 279-82, 2005.
- Kim JH, Tuziak T, Hu L, Wang Z, Bondaruk J, Kim M, Fuller G, Dinney C, Grossman HB, Baggerly K, Zhang W, Czerniak B, “Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways”, Lab Invest, vol. 85, no. 4, pp. 532-49, 2005.
- Shim YH, Bae SH, Kim JH, Kim KR, Kim CJ, Paik YK, “A novel mutation of the human 7-dehydrocholesterol reductase gene reduces enzyme activity in patients with holoprosencephaly”, Biochem Biophys Res Commun, vol. 315, no. 1, pp. 219-23, 2004.
- Park KS, Kang KC, Kim KY, Jeong PY, Kim JH, Adams DJ, Kim JH, Paik YK, “HWY-289, a novel semi-synthetic protoberberine derivative with multiple target sites in Candida albicans”, J Antimicrob Chemother, vol. 47, no. 5, pp. 513-9, 2001.
- Kim JH, Lee JN, Paik YK, “Cholesterol biosynthesis from lanosterol. A concerted role for Sp1 and NF-Y-binding sites for sterol-mediated regulation of rat 7-dehydrocholesterol reductase gene expression”, J Biol Chem, vol. 276, no. 21, pp. 18153-60, 2001.
Contact Information
Email: jaihyunk@uci.edu
Phone: (949) 824-9774
Address: 3121 Falling Leaves Foundation Medical Innovation Bldg, Irvine
Return to topThis profile was created with the help of AI.
Last updated on 5/1/2026.